HTG Molecular Diagnostics Receivables

HTG Molecular Diagnostics (HTGMQ) currently reports a receivables of $1.1M as of March 2023. That compares with $750K in the prior-year period — up 51.1% year over year. Use the charts on this page to explore HTG Molecular Diagnostics's receivables history and peer comparisons.

HTG Molecular Diagnostics's receivables increased from $750K to $1.1M — a 51.1% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HTG Molecular Diagnostics reported $1.1M in receivables as of March 2023. That compares with $750K in the prior-year period — up 51.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for HTG Molecular Diagnostics, and consider following HTGMQ for alerts when major investors trade the stock.

HTG Molecular Diagnostics is classified in the Healthcare sector. On receivables, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HTGMQ with unrelated industries.